Cantor Fitzgerald Weighs in on LMAT FY2025 Earnings

LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Cantor Fitzgerald issued their FY2025 earnings estimates for LeMaitre Vascular in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the medical instruments supplier will post earnings of $2.22 per share for the year. Cantor Fitzgerald currently has a “Neutral” rating and a $96.00 target price on the stock. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.94 per share.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. During the same period in the previous year, the firm earned $0.33 EPS. The company’s quarterly revenue was up 15.6% compared to the same quarter last year.

LMAT has been the subject of several other reports. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Oppenheimer restated an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, Barrington Research raised their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Stock Down 1.7 %

LMAT opened at $96.31 on Wednesday. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of 52.63, a P/E/G ratio of 2.19 and a beta of 0.96. LeMaitre Vascular has a twelve month low of $56.04 and a twelve month high of $109.58. The company has a 50-day simple moving average of $98.18 and a 200 day simple moving average of $92.23.

Insider Transactions at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the sale, the director now owns 2,278 shares in the company, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Large investors have recently bought and sold shares of the company. Glenmede Trust Co. NA increased its stake in shares of LeMaitre Vascular by 1.3% in the third quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier’s stock valued at $976,000 after buying an additional 136 shares during the period. Summit Global Investments increased its position in LeMaitre Vascular by 2.4% in the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock valued at $575,000 after acquiring an additional 146 shares during the period. NBC Securities Inc. raised its stake in shares of LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 183 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 188 shares during the period. Finally, MML Investors Services LLC lifted its holdings in shares of LeMaitre Vascular by 2.8% during the third quarter. MML Investors Services LLC now owns 7,107 shares of the medical instruments supplier’s stock worth $660,000 after purchasing an additional 191 shares during the period. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.